Gilead Sciences

YTD

ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

CEO

Daniel P. O'Day

CEODaniel P. O'Day

Employees

17,000

Employees17,000

Headquarters

Foster City, California

HeadquartersFoster City, California

Founded

1987

Founded1987

Employees

17,000

Employees17,000

GILD Key Statistics

Market cap

160.97B

Market cap160.97B

Price-Earnings ratio

17.86

Price-Earnings ratio17.86

Dividend yield

2.45%

Dividend yield2.45%

Average volume

9.46M

Average volume9.46M

High today

$132.90

High today$132.90

Low today

$127.89

Low today$127.89

Open price

$132.88

Open price$132.88

Volume

10.73M

Volume10.73M

52 Week high

$157.29

52 Week high$157.29

52 Week low

$107.75

52 Week low$107.75

Stock Snapshot

The current Gilead Sciences(GILD) stock price is $129.10, with a market capitalization of 160.97B. The stock trades at a price-to-earnings (P/E) ratio of 17.86 and offers a dividend yield of 2.45%.

On 2026-07-06, Gilead Sciences(GILD) stock moved within a range of $127.89 to $132.90. With shares now at $129.10, the stock is trading +0.9% above its intraday low and -2.9% below the session's peak.

Trading volume for Gilead Sciences(GILD) stock has reached 10.73M, versus its average volume of 9.46M.

Over the past 52 weeks, Gilead Sciences(GILD) stock has traded between a high of $157.29 and a low of $107.75.

GILD News

Benzinga 7h

Generic Fears Overdone? Gilead Stock Has More Room to Run, Analyst Says

HSBC upgraded Gilead Sciences Inc. (NASDAQ:GILD) on Monday, citing that the consensus is ‘too pessimistic’ in its assumptions of continued decline once dolutegr...

Benzinga 7h

What's Going on With Gilead Sciences Stock Monday? - Gilead Sciences - Benzinga

...

TipRanks 15h

Gilead upgraded to Buy from Hold at HSBC

HSBC analyst Morten Herholdt upgraded Gilead (GILD) to Buy from Hold with a price target of $155, up from $133. The market is too pessimistic on the HIV market...

Analyst ratings

83%

of 29 ratings

Buy

82.8%

Hold

17.2%

Sell

More GILD News

Simply Wall St 24h

Should First-Line Trodelvy Breast Cancer Approvals Reshape the Gilead Sciences Investment Narrative?

In late June 2026, Gilead Sciences reported that the FDA and European Commission approved Trodelvy for first-line treatment of unresectable locally advanced or...

Nasdaq 5d

Gilead Sciences, Inc. Is a Trending Stock: Facts to Know Before Betting on It

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affe...

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.